Overview
- Peptide (C)ELGYQTNFHQAINDAH, corresponding to amino acid residues 259 - 274 of mouse PTAFR (Accession Q62035). Extracellular, 3rd loop.
- Western blot analysis of rat brain membranes (lanes 1 and 3) and mouse brain membranes (lanes 2 and 4):1-2. Anti-Platelet-activating factor receptor (extracellular) Antibody (#APR-055), (1:500).
3-4. Anti-Platelet-activating factor receptor (extracellular) Antibody, preincubated with Platelet-activating factor receptor (extracellular) Blocking Peptide (BLP-PR055). - Western blot analysis of human THP-1 monocytic leukemia cell line lysate (lanes 1 and 3) and human MEG-01 megakaryoblastic leukemia cell line lysate (lanes 2 and 4):1-2. Anti-Platelet-activating factor receptor (extracellular) Antibody (#APR-055), (1:500).
3-4. Anti-Platelet-activating factor receptor (extracellular) Antibody, preincubated with Platelet-activating factor receptor (extracellular) Blocking Peptide (BLP-PR055).
- Expression of Platelet-activating factor receptor in rat substantia nigra pars compacta (SNC).Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-Platelet-activating factor receptor (extracellular) Antibody (#APR-055), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. PAFR immunoreactivity (green) appears in SNC neurons (arrows). B. Pre-incubation of the antibody with Platelet-activating factor receptor (extracellular) Blocking Peptide (BLP-PR055), suppressed staining. Cell nuclei are stained with DAPI (blue).
- Cell surface detection of PAFR by indirect flow cytometry in live intact human THP-1 monocytic leukemia cell line:___ Cells.
___ Cells + goat-anti-rabbit-FITC.
___ Cells + Anti-Platelet-activating factor receptor (extracellular) Antibody (#APR-055) (2.5μg) + goat-anti-rabbit-FITC.
- Walterscheid, J.P. et al. (2002) J. Exp. Med., 195, 171.
- Cao, C. et al. (2018) Nat. Struct. Mol. Biol., 25, 488.
- Correa-Costa, M. et al. (2014) Lab. Invest., 94, 455.
- Melnikova, V. et al. (2007) Cancer. Metastasis. Rev., 26, 359.
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid mediator that was first described by its ability to cause platelet aggregation and dilation of blood vessels. In addition, PAF acts as a mediator of cell-to-cell communication, inflammation, allergic responses and shock1.
PAF acts on PAF receptor (PAFR) a G protein-coupled receptor (GPCR). It consists of 7 transmembrane-spanning domains (TMDs), and two potential N-linked glycosylation sites. PAFR was found to expressed in the lung, neutrophils, monocytes, macrophages, placenta, small intestine, heart, liver, kidney, brain, and spleen. As a results of PAF interaction, PAFR is coupled to Gq protein and consequently activates various downstream signaling pathways2.
Experiments in both PAF receptor knockout animals and transgenic animals overexpressing PAF receptors support the pathophysiological role attributed to PAF receptor signaling. For example, Mice model of obstructive nephropathy show that PAFR signaling contributes to a pro-inflammatory environment leading to renal dysfunction and progressive organ failure3. In addition, inhibition of PAFR signaling results in an effective inhibition of experimental tumor growth and metastasis4.
Application key:
Species reactivity key:
Anti-Platelet-activating factor receptor (extracellular) Antibody (#APR-055) is a highly specific antibody directed against an extracellular epitope of the mouse protein. The antibody can be used in western blot, immunohistochemistry and flow cytometry applications. It has been designed to recognize PAFR from rat, mouse and human samples.